ArticleMedical oncology (Northwood, London, England)2015
Effect of metabolic syndrome and its components on recurrence and survival in early-stage non-small cell lung cancer.
Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have indicated that clustering of components of metabolic syndrome (MetS) increases the risk for the development of several cancers such as colon, prostate, and breast cancer. However, the prognostic role of MetS in early-stage non-small cell lung cancer (NSCLC) has not been well defined. We reviewed the clinical data and pre-treatment information of MetS of 545 patients with NSCLC who underwent radical surgery and were pathologically diagnosed as stage IB of NSCLC. The influence of MetS and/or its components on survival outcome was examined using Kaplan-Meier and Cox proportional hazards analyses. The patients with MetS showed no difference in survival outcome regarding overall survival (OS) and disease-free survival (DFS) compared with patients without MetS in univariate, multivariate, and stratification analyses. However, in univariate analysis, a high high density lipoprotein level was a good prediction factor for DFS (median DFS with vs. without MetS: 124.3 vs. 115.1 months P = 0.036). Other single MetS components showed no association with OS and DFS in early-stage NSCLC. For other clinical characteristic, the age and adjuvant therapy were the independent prognostic factors of OS in univariate and multivariate analyses. MetS and/or its components do not have significant prognostic value in early-stage NSCLC.
Indexed as
Identifiers
25476482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.